Analyst Jonathan Chang from Leerink Partners reiterated a Buy rating on Zai Lab (ZLAB – Research Report) and keeping the price target at ...

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 46%. Looking ahead, ...

Limited announced that it has commenced an underwritten public offering of $200M of American depositary shares, ADSs, each ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

Zai Lab announces $200M share offering amid 47% revenue growth and plans for KarXT submission in China. Multiple companies report changes: Kronos Bio seeks alternatives, Allogene halts trial ...

Zai Lab Ltd (HK:9688) has released an update. Zai Lab Limited has announced a proposed follow-on underwritten public offering of $200 million ...

Zai Lab Ltd (HK:9688) has released an update. Zai Lab Limited has updated its risk factors in a new Form 8-K filing with the U.S. Securities ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zai Lab (ZLAB – Research Report), NeuroPace (NPCE – Research Report) and CervoMed (CRVO – Research ...

Zai Lab (NASDAQ:ZLAB) stock rose 5% in early trading Monday after the company announced that Vyvgart Hytrulo’s regulatory ...

The business’s 50 day simple moving average is $25.16 and its 200 day simple moving average is $20.68. Zai Lab has a 1 year ...

Zai Lab Ltd ( (ZLAB)) has released its Q3 earnings. Here is a breakdown of the information Zai Lab Ltd presented to its investors. Zai Lab Limited is a biopharmaceutical company based in China and the ...

SHANGHAI & CAMBRIDGE, Mass., November 13, 2024--(BUSINESS WIRE)--Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB; ...